Abstract:Objective To investigate the clinical effect of edaravone combined with butylphthalide injection and butylphthalide capsule sequential therapy in the treatment of acute progressive cerebral infraction.? Methods A total of 98 patients with acute progressive cerebral infraction who were in hospital from January 2015 to December 2016 was divided into study group (n=50) and control group (n=48) according to treatment. Patients in control group were treated with regular antiplatelet aggregation, improving circulation, expending the blood volume and neuroprotective drugs and edaravone. The patients in the study group were treated with butylphthalide injection and capsule on the basis of the control group treatment. The nerve defect condition, daily life ability, blood rheology index, blood coagulation index and quality of life (QOL) before and after treatment and overall treatment effect were observed in the two groups.? Results After the treatment, National Institute of Health stroke scale (NIHSS), fibrinogen (FIB), whole blood viscosity (WBV) at high shear rate (HSR) and low shear rate (LSR) and hematocrit value (HCT) in study group were significant lower than those in control group ［(7.80±1.24) points vs(14.37±5.89)points, (3.01±0.47)g/L vs (4.08±0.51)g/L, (4.04±1.17)mPa·s vs (5.90±0.92)mPa·s, (15.80±4.17)mPa·s vs (49.16±5.36)mPa·s, (38.83±4.89)% vs (45.13±4.71)%, all P<0.01], and Barthel scale, apparent rate and total effictive ratein study group were higher than those in control group (84.17±6.31 vs 76.82±5.37, 76.0% vs 47.9%, 90.0% vs 75.0%, all P<0.05). Six months after the treatment, the total score of QOL in study group was higher than that in control group(40.38±7.16 vs 33.10±6.25, P<0.01).? Conclusion Edaravone combined with butylphthalide injection and butylphthalide capsule sequential therapy has a remarkable effect in the treatment of acute progressive cerebral infraction.